01:46pm Sunday 19 August 2018
01/22/2018
Cancers

Starving Tumors: New Target Discovered

Actively growing tumors have a high demand for oxygen and nutrients. Therefore, they stimulate the growth of blood vessels. This process is called angiogenesis. If tumor-associated angiogenesis is suppressed, this may limit tumor growth. Scientists from the German Cancer Research Center and the European Center for Angioscience at Heidelberg University have now discovered a new target for anti-angiogenic tumor therapy. They show that the deletion of a signaling molecule in mice leads to the formation of less blood vessels in late-stage tumors. This delays their growth and limits the formation of metastases.

The microscopic analysis reveals a dense network of blood vessels in a growing tumor. © La Porta, DKFZ

Like all cells in our body, cancer cells require nutrients and oxygen, which are delivered by blood vessels. Since cancer cells divide particularly fast, new blood vessels need to grow rapidly and in an uncontrolled fashion into the tumor. Blocking this process could limit tumor growth. Scientists in the laboratory of Hellmut Augustin have now shown that the receptor Tie1 plays a crucial role in angiogenesis. Tie1 is expressed by endothelial cells, the cells lining the inside of all blood vessels. Tie1 interacts with other signaling molecules and thereby controls the growth of blood vessels.

Tie1 is overexpressed in the vasculature of tumors. This contributes to the growth of blood vessels and enables tumor growth. Surprisingly, the growth promoting effect of Tie1 occurs only at later stages of tumor growth. In genetically engineered mice, whose endothelial cells could not express Tie1, tumors growth was initially unaltered. Yet, after two weeks, when tumors had grown to substantial size, their growth in mice without Tie1 was remarkably slowed. This could be an advantage for the later clinical exploitation of Tie1 as a therapeutic target: “Tumors are mostly diagnosed in patients, when they are fairly advanced in their evolution” explains Augustin. “It is therefore particularly important to identify therapeutic targets that are active at later stages of tumor growth, as demonstrated here for Tie1.”

Targeting of Tie1 has another positive effect: It stabilizes the walls of the blood vessels and thereby prevents the formation of metastases. Metastases are responsible for the majority of cancer deaths. Such secondary tumors arise when cancer cells leave the primary tumor, enter into the bloodstream, and then reach distant organs. They can stay dormant at the secondary site for weeks or even years, before they again start to divide to grow a metastasis. “We deleted Tie1 genetically to block tumor growth and metastasis”, explains Silvia La Porta, the study’s lead scientist. “Next, we will study, if blocking of Tie1 by a drug has the same beneficial effect”.

As shown in the study, following surgical removal of the primary tumor, 10 out of 14 normal control mice developed metastases. In mice without Tie1, only 1 out of 14 animals had metastases.

The exact mechanism of action of Tie1 is still the subject of intensive research. The molecule is a so called orphan receptor, which means that it is a receptor for which there is no known binding partner. Future studies will need to shed light into Tie1’s enigmatic functions.

The concept of blocking angiogenesis is not novel. In 2004, the drug Bevacizumab (Avastin) received clinical approval. It limits tumor growth by blocking the angiogenic factor vascular growth factor (VEGF). The efficacy of Bevacizumab is, however, limited. That’s why scientists are intensely studying second generation anti-angiogenic targets that could be used in combination therapy to improve the efficacy of anti-angiogenic intervention.

The pharmaceutical industry has in recent years intensely studied Angiopoietin2 as a therapeutic target. Clinical studies with Angiopoietin2 blocking drugs yielded, however, disappointing results. Unlike Tie1, Ang2 affects primarily the early stages of tumor development, which could be one of the reasons for its limited clinical efficacy. Given that Tie1 targets a different therapeutic window, future studies will need to show if it could prove to be a better therapeutic target.

Silvia La Porta, Lise Roth, Mahak Singhal, Carolin Mogler, Carleen Spegg, Benjamin Schieb, Xianghu Qu, Ralf H. Adams, H. Scott Baldwin, Soniya Savant, and Hellmut G. Augustin: Endothelial Tie1–mediated angiogenesis and vascular abnormalization promote tumor progression and metastasis. Journal of Clinical Investigation 2018, DOI: 10.1172/JCI94674.

A picture is available for download:
http://www.dkfz.de/de/presse/pressemitteilungen/2018/bilder/PM-JCI-LaPorta-et-al.jpg

Caption: The microscopic analysis reveals a dense network of blood vessels in a growing tumor.

Note on use of images related to press releases
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: “Source: La Porta, DKFZ”.
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ’s Press Office (phone: ++49-(0)6221 42 2854, E-mail: presse@dkfz.de). Any commercial use is prohibited.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

 

 


Share on:
or:

Health news